Patents by Inventor Stuart Aaronson

Stuart Aaronson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11273151
    Abstract: The present invention relates to methods of treating a tumor or treating cancer in a subject having a p53 DNA contact mutation that involve administering, to the subject, a ROCK inhibitor. Also disclosed is a method of identifying a subject as a candidate for such treatment.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 15, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Stuart Aaronson, Albino Troilo, Davide Esposito
  • Patent number: 11246868
    Abstract: The present invention relates to a method of treating a tumor in a subject. This method involves administering to a subject having a Hippo pathway mutant tumor a tankyrase inhibitor, where the tumor is susceptible to treatment with the tankyrase inhibitor, and said administering is carried out to treat the tumor. The present invention also relates to a method of treating cancer in a subject, and a method of identifying a subject as a candidate for treatment.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: February 15, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Stuart A. Aaronson, Albino Troilo, Erica K. Benson
  • Publication number: 20200237736
    Abstract: The invention relates to methods for preventing or treating resistance to EGFR inhibitors in cancer patients. More particularly, after performing a screen for small molecules potentially capable of countering cancer resistance to EGFR TKI, inventors identified the multikinase inhibitor sorafenib, which has the property, in combination with EGFR TKI, to prevent the enrichment of tumor cells containing mutations responsible for NSCLC resistance to first and third generation EGFR TKI. These data indicate that this multikinase inhibitor can prevent resistance to several generations of EGFR TKI. These in vitro data were confirmed in an in vivo xenograft mouse model of NSCLC. Finally these data were reproduced in cancer cells using SC-1, a sorafenib analogue.
    Type: Application
    Filed: June 22, 2018
    Publication date: July 30, 2020
    Inventors: Luca GRUMOLATO, Alexis GUERNET, Stuart AARONSON, Youssef ANOUAR
  • Publication number: 20190125748
    Abstract: The present invention relates to a method of treating a tumor in a subject. This method involves administering to a subject having a Hippo pathway mutant tumor a tankyrase inhibitor, where the tumor is susceptible to treatment with the tankyrase inhibitor, and said administering is carried out to treat the tumor. The present invention also relates to a method of treating cancer in a subject, and a method of identifying a subject as a candidate for treatment.
    Type: Application
    Filed: April 26, 2017
    Publication date: May 2, 2019
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Stuart A. AARONSON, Albino TROILO, Erica K. BENSON
  • Publication number: 20180318272
    Abstract: The present invention relates to methods of treating a tumor or treating cancer in a subject having a p53 DNA contact mutation that involve administering, to the subject, a ROCK inhibitor. Also disclosed is a method of identifying a subject as a candidate for such treatment.
    Type: Application
    Filed: November 3, 2016
    Publication date: November 8, 2018
    Inventors: Stuart AARONSON, Albino TROILO, Davide ESPOSITO
  • Publication number: 20160274120
    Abstract: The invention demonstrates that canonical Wnt signaling is activated in certain primary tumors and tumor cell lines in the absence of ?-catenin or APC mutations and that inhibition of such activated canonical Wnt signaling in such tumor cells inhibits tumor growth and, at least in some cases, induces death of tumor cells. As further demonstrated herein, the activation of canonical Wnt signaling is associated with a higher rate of cancer recurrence in patients with Stage I Non-Small Cell Lung Cancer (NSCLC), which provides a new method for cancer prognosis, wherein activation of canonical Wnt signaling reflects a more aggressive tumor phenotype suggesting the need for a more aggressive therapy.
    Type: Application
    Filed: March 23, 2016
    Publication date: September 22, 2016
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Stuart Aaronson, Gal Akiri, Sapna Vijayakumar
  • Patent number: 8809287
    Abstract: The present invention relates to compounds and methods for treating cancers in which the autocrine Wnt canonical signaling pathway is activated. In particular, there is provided a method for inhibiting growth of a tumor cell or sensitizing a cancer cell to treatment by contacting such a tumor cell with a compound that alters Wnt signaling. The compound that alters Wnt signaling can be a Wnt antagonist, a Wnt receptor antagonist, or a combination thereof.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: August 19, 2014
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Anna Bafico, Stuart Aaronson
  • Publication number: 20140113006
    Abstract: The invention demonstrates that canonical Wnt signaling is activated in certain primary tumors and tumor cell lines in the absence of ?-catenin or APC mutations and that inhibition of such activated canonical Wnt signaling in such tumor cells inhibits tumor growth and, at least in some cases, induces death of tumor cells. As further demonstrated herein, the activation of canonical Wnt signaling is associated with a higher rate of cancer recurrence in patients with Stage I Non-Small Cell Lung Cancer (NSCLC), which provides a new method for cancer prognosis, wherein activation of canonical Wnt signaling reflects a more aggressive tumor phenotype suggesting the need for a more aggressive therapy.
    Type: Application
    Filed: April 19, 2010
    Publication date: April 24, 2014
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE
    Inventors: Stuart Aaronson, Gal Akiri, Sapna Vijayakumar
  • Patent number: 7838216
    Abstract: The isolation, cloning and characterization of a human gene related to but distinct from EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes have also been described.
    Type: Grant
    Filed: October 21, 1987
    Date of Patent: November 23, 2010
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: C. Richter King, Matthias H. Kraus, Stuart A. Aaronson
  • Patent number: 7605127
    Abstract: The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: October 20, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Andrew M. L. Chan, Jeffrey S. Rubin, Donald P. Bottaro, Stuart A. Aaronson, Stephen J. Stahl, Paul T. Wingfield, Vittoria Cioce
  • Publication number: 20090163407
    Abstract: The present invention relates to compounds and methods for treating cancers in which the autocrine Wnt canonical signaling pathway is activated. In particular, there is provided a method for inhibiting growth of a tumor cell or sensitizing a cancer cell to treatment by contacting such a tumor cell with a compound that alters Wnt signaling. The compound that alters Wnt signaling can be a Wnt antagonist, a Wnt receptor antagonist, or a combination thereof.
    Type: Application
    Filed: November 15, 2005
    Publication date: June 25, 2009
    Applicant: Mount Sinai School of Medicine of New York University
    Inventors: Anna Bafico, Stuart Aaronson
  • Publication number: 20080293053
    Abstract: Methods and compositions for the treatment of soft tissue cancer are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of DKK-1 using shRNA or siRNA molecules will be effective at reducing the cancer phenotype of prostate cancer cells.
    Type: Application
    Filed: December 28, 2007
    Publication date: November 27, 2008
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Evan T. Keller, Christopher L. Hall, Stuart A. Aaronson
  • Patent number: 7427671
    Abstract: A DNA sequence which encodes a human type ? platelet derived growth factor receptor protein which preferentially binds to the AA homodimer and AB heterodimer forms of platelet derived growth factor and also binds the BB homodimer at high affinity, is described. Substantially pure human a platelet derived growth factor receptor protein and methods for recombinantly producing human ? platelet derived growth factor receptor protein are also described.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: September 23, 2008
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Publication number: 20070253963
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
    Type: Application
    Filed: October 25, 2006
    Publication date: November 1, 2007
    Applicant: The Government of U.S.A. as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Rubin, Paul Finch, Stuart Aaronson
  • Patent number: 7252929
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: August 7, 2007
    Assignee: United States of America, as represented by the Secretary, Dept of Health & Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Publication number: 20070060515
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
    Type: Application
    Filed: February 3, 2006
    Publication date: March 15, 2007
    Applicants: Department of Health and Human Services
    Inventors: Jeffrey Rubin, Paul Finch, Stuart Aaronson
  • Patent number: 7183377
    Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: February 27, 2007
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey S. Rubin, Paul Finch, Stuart Aaronson, Xi He
  • Patent number: 7026291
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 11, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey S. Rubin, Paul W. Finch, Stuart A. Aaronson
  • Publication number: 20050112582
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Application
    Filed: November 3, 2003
    Publication date: May 26, 2005
    Inventors: Toshimitsu Matsui, Stuart Aaronson, Jacalyn Pierce
  • Patent number: 6833132
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: December 21, 2004
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jeffrey S. Rubin, Paul W. Finch, Stuart A. Aaronson